Praluent vs Lisinopril Side Effects: A Head-to-Head Comparison

What Are These Two Drugs and Why Compare Them?

Alirocumab and lisinopril are rarely prescribed for the same condition, yet clinicians and patients frequently ask how their tolerability profiles stack up. The comparison matters most when a cardiologist is building a multi-drug regimen for a patient who already has one of these agents and needs to anticipate additive or competing side-effect burdens.

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, preventing LDL receptor degradation and lowering LDL cholesterol by 48 to 62% on top of background statin therapy. Lisinopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing blood pressure, cardiac afterload, and proteinuria. The FDA approved alirocumab in 2015 and lisinopril has been approved since 1987.

No published randomized controlled trial has directly compared the two agents head-to-head in the same population, because their approved indications do not overlap. Every comparison below is synthesized across their respective key trials.

Mechanism Shapes Tolerability

Subcutaneous biologics like alirocumab produce local tissue reactions and immune-mediated responses. Oral small molecules like lisinopril act on the renin-angiotensin-aldosterone system systemically, producing class-effects (cough, angioedema, hyperkalemia) that are entirely absent from PCSK9 inhibitor pharmacology.

Who Gets Prescribed Each Drug

A patient with a recent acute coronary syndrome on atorvastatin 80 mg who cannot reach LDL <70 mg/dL might receive alirocumab. A patient with stage 2 hypertension and microalbuminuria would typically receive lisinopril first-line. Many high-risk cardiac patients are on both simultaneously.

Alirocumab (Praluent) Side-Effect Profile

The most complete safety dataset for alirocumab comes from the ODYSSEY OUTCOMES trial (N=18,924), which enrolled post-ACS patients randomized to alirocumab 75 to 150 mg every 2 weeks versus placebo, all on high-intensity statin therapy, followed for a median of 2.8 years.

Injection-Site Reactions

Injection-site reactions were the single most distinguishing adverse event in ODYSSEY OUTCOMES, occurring in 7.2% of the alirocumab group versus 5.1% in the placebo group. These reactions, which include redness, bruising, and mild swelling at the subcutaneous injection site, were rarely severe enough to cause discontinuation. Patients who rotate injection sites between the abdomen, thigh, and upper arm report lower rates of localized irritation.

Flu-Like Symptoms and Upper Respiratory Infections

Upper respiratory tract infections (URTIs) appeared at 8.5% in alirocumab-treated patients versus 7.5% in placebo groups across the ODYSSEY program. Whether this represents a true immunologic signal or background event rate remains debated. The FDA prescribing information does list nasopharyngitis and URTIs as common adverse events. The prescribing label notes these occurred at rates above 2% in clinical trials.

Neurocognitive Concerns

Post-marketing reports and some ODYSSEY program analyses flagged neurocognitive adverse events, including memory impairment and confusion, at a numerically higher rate in PCSK9-inhibitor-treated patients. A dedicated neurocognitive sub-study found no statistically significant difference in cognitive test scores at 24 months. The FDA still requires post-market neurocognitive surveillance for this drug class.

Hypersensitivity Reactions

Serious hypersensitivity reactions, including hypersensitivity vasculitis and rare anaphylaxis, have been reported post-market. These occurred in <1% of trial participants. Patients with known hypersensitivity to any component of the formulation should not receive alirocumab.

What Alirocumab Does Not Do

Alirocumab does not cause cough, angioedema, hyperkalemia, or renal function decline. These absences become clinically relevant when a patient cannot tolerate lisinopril and needs an alternative for LDL-C reduction rather than blood pressure control.

Lisinopril Side-Effect Profile

Lisinopril's safety record is one of the most thoroughly characterized of any cardiovascular drug, partly because ALLHAT (N=42,418) compared lisinopril head-to-head against chlorthalidone and amlodipine over 4.9 years, generating some of the largest comparative safety data in cardiovascular pharmacology.

The ACE Inhibitor Cough

Dry, persistent, non-productive cough is the most common reason patients discontinue lisinopril. Estimates range from 5 to 15% in predominantly White populations to as high as 30 to 40% in East Asian populations, a difference attributed to bradykinin metabolism genetics. The 2023 ACC/AHA Hypertension Guideline formally recommends switching to an angiotensin receptor blocker (ARB) when ACE inhibitor cough is intolerable, rather than dose reduction.

Angioedema

Angioedema is rare but potentially life-threatening. The incidence is approximately 0.1 to 0.7% across ACE inhibitor users, and Black patients have a 3 to 5 times higher relative risk compared to White patients. A 2017 analysis confirmed ACE-inhibitor-associated angioedema disproportionately affects patients of African descent, with Black patients representing 40 to 50% of all angioedema emergency visits despite lower overall ACE inhibitor prescription rates. Lisinopril is absolutely contraindicated in patients with prior ACE inhibitor-induced angioedema.

Hyperkalemia and Renal Effects

Lisinopril reduces aldosterone secretion, which can raise serum potassium. Clinically significant hyperkalemia (>5.5 mEq/L) occurs in approximately 2 to 4% of patients on standard doses, rising sharply when combined with potassium-sparing diuretics, NSAIDs, or in patients with chronic kidney disease. Serum creatinine may rise 10 to 20% at initiation, which is generally an expected hemodynamic effect rather than true nephrotoxicity, but requires monitoring.

Hypotension

First-dose hypotension is documented in patients with volume depletion, high-renin states, or concurrent diuretic use. ALLHAT reported that lisinopril produced slightly higher rates of hospitalized heart failure versus chlorthalidone (8.7% vs 7.7%, P<0.001 when adjusted), a finding attributed partly to less effective blood pressure control at trial initiation rather than a direct toxicity of the drug.

Pregnancy Contraindication

Lisinopril carries a Black Box Warning for fetal harm. Use during the second and third trimesters causes fetal renal dysgenesis, oligohydramnios, skull hypoplasia, and death. Any woman of childbearing potential prescribed lisinopril needs reliable contraception and immediate drug discontinuation upon confirmed pregnancy.

Direct Side-Effect Profile Comparison

The table below summarizes the major adverse events for each drug based on trial and post-market data. No direct head-to-head trial exists for this comparison.

| Adverse Effect | Alirocumab (Praluent) | Lisinopril | |---|---|---| | Dry cough | Not reported | 5 to 15% (up to 40% in Asian populations) | | Angioedema | Not reported | 0.1 to 0.7%; 3 to 5x higher risk in Black patients | | Injection-site reaction | 7.2% (ODYSSEY OUTCOMES) | N/A (oral drug) | | Hyperkalemia | Not reported | 2 to 4% on standard doses | | Hypotension | Not reported | Yes; first-dose effect; volume-dependent | | Neurocognitive events | Post-market signal; no confirmed difference in RCTs | Not reported | | Flu-like / URTI | 8.5% (ODYSSEY program) | Not typical | | Pregnancy risk | No known fetal harm | Black Box Warning: fetal renal dysplasia | | Serious hypersensitivity | <1%; rare anaphylaxis | Angioedema risk (above) | | Renal function | No decline observed in trials | Expected 10 to 20% creatinine rise at initiation |

Cardiovascular Efficacy: What the Trials Show

ODYSSEY OUTCOMES: Alirocumab Post-ACS

In ODYSSEY OUTCOMES, 18,924 patients with recent ACS on maximum-tolerated statin were randomized to alirocumab or placebo. The primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) occurred in 9.5% of alirocumab patients versus 11.1% in the placebo group, representing a 15% relative risk reduction (HR 0.85; 95% CI 0.78 to 0.93; P<0.001). All-cause mortality also showed a nominal reduction (3.5% vs 4.1%), though the pre-specified hierarchical testing made this a secondary finding.

The NEJM publication noted: "Alirocumab reduced the risk of major adverse cardiovascular events... With a greater absolute risk reduction in patients with a baseline LDL cholesterol level of 100 mg per deciliter or more."

ALLHAT: Lisinopril in Hypertension

ALLHAT randomized 42,418 patients aged 55 or older with hypertension and at least one additional CHD risk factor to chlorthalidone, amlodipine, lisinopril, or doxazosin. For the primary outcome (fatal CHD or nonfatal MI), lisinopril was equivalent to chlorthalidone (RR 0.99; 95% CI 0.91 to 1.08). The JAMA report stated: "Thiazide-type diuretics are superior in preventing one or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy."

Lisinopril showed a significantly higher rate of stroke (RR 1.15; 95% CI 1.02 to 1.30) compared to chlorthalidone, attributed to less effective blood pressure lowering in Black patients randomized to lisinopril. This is a population-specific finding and does not disqualify lisinopril for the broader hypertensive population.

Efficacy in Context

These trials answer different clinical questions. Alirocumab targets residual LDL risk after a coronary event in statin-treated patients. Lisinopril addresses primary blood pressure control, post-MI left ventricular remodeling, and nephroprotection. A cardiologist managing a patient after ACS with hypertension and proteinuria might use both drugs simultaneously without conflict.

Which Patients Should Avoid Each Drug

Contraindications to Alirocumab

Patients with a known serious hypersensitivity to alirocumab or any ingredient in the formulation should not receive it. No pregnancy category equivalent exists under the current FDA labeling system, but animal reproductive studies were inconclusive and human data are limited; the package insert advises weighing risk versus benefit.

Contraindications to Lisinopril

Lisinopril is contraindicated in pregnancy (Black Box Warning), in patients with prior ACE inhibitor-induced angioedema, in patients with hereditary or idiopathic angioedema, and when co-administered with aliskiren in patients with diabetes. It is also contraindicated with sacubitril/valsartan (Entresto) within 36 hours of the last dose due to additive angioedema risk.

Tolerability in Special Populations

Patients With Chronic Kidney Disease

Alirocumab does not require dose adjustment in CKD. Lisinopril requires cautious titration and close potassium and creatinine monitoring. In patients with GFR <30 mL/min/1.73m², the hyperkalemia and renal deterioration risk with lisinopril rises significantly.

Older Adults (Age 65+)

Both drugs are used in older adults. Lisinopril carries a higher first-dose hypotension risk in patients aged 65+, particularly those on diuretics. Alirocumab has not shown age-related increases in adverse events in post-hoc analyses of ODYSSEY OUTCOMES.

Black Patients

Black patients face higher angioedema risk with lisinopril and show attenuated blood pressure response to ACE inhibitors as a class, a pharmacogenomic effect related to lower average renin levels. The 2023 ACC/AHA Hypertension Guideline recommends thiazide-type diuretics or calcium channel blockers as preferred first-line agents in Black patients without compelling indications for an ACE inhibitor. Alirocumab efficacy does not appear to vary by race in available trial data.

Practical Prescribing Considerations

The following decision framework synthesizes the tolerability data above for common clinical scenarios:

Scenario 1: Post-ACS patient, LDL >70 mg/dL on maximally tolerated statin, normotensive. Alirocumab is the appropriate add-on. Lisinopril has no primary indication here unless post-MI LV dysfunction is present (EF <40%).

Scenario 2: Hypertensive patient with microalbuminuria, no ASCVD event. Lisinopril (or another ACE inhibitor) is first-line per guidelines. Alirocumab is not indicated unless LDL goals are unmet.

Scenario 3: Post-ACS patient with hypertension, LDL >70 mg/dL, and proteinuria. Both drugs are likely indicated. Begin lisinopril for BP and renal protection. Add alirocumab after confirming LDL target is not met on statin. Monitor potassium and renal function monthly for the first 3 months.

Scenario 4: Patient who cannot tolerate lisinopril due to cough. Switch to an ARB (e.g., losartan 50 mg daily) for BP control. Alirocumab addresses LDL, not blood pressure, so it does not substitute for lisinopril's antihypertensive or nephroprotective role.

Cost, Access, and Adherence Factors

Lisinopril is generic and costs approximately $4 to 10 per month at most U.S. Pharmacies, making it one of the most affordable cardiovascular medications available. Alirocumab's list price is approximately $5,850 per year, though manufacturer copay assistance programs and prior authorization pathways frequently reduce out-of-pocket cost to under $20 per month for commercially insured patients.

Adherence data from post-market studies suggest that injection-based therapies like alirocumab are discontinued at higher rates than oral drugs over 12 months when injection-site discomfort is not managed. Conversely, the ACE inhibitor cough drives lisinopril discontinuation at rates that can exceed 15% in outpatient practice, representing a major real-world adherence gap for oral antihypertensives.

Summary of Key Differences

Alirocumab and lisinopril have non-overlapping side-effect profiles because they act through completely different mechanisms. The drugs are additive in high-risk patients. For a patient who tolerates neither lisinopril nor alirocumab, an ARB replaces lisinopril for BP/renal indications while alirocumab can be substituted with evolocumab (another PCSK9 inhibitor) or inclisiran (a small interfering RNA targeting PCSK9) if the issue is injection-site reactions rather than a class-wide intolerance.

Patients experiencing ACE inhibitor cough on lisinopril do not need to avoid alirocumab. Those with prior PCSK9 inhibitor hypersensitivity reactions are not at increased risk from ACE inhibitors. The two drug classes simply do not share a mechanism or a meaningful overlap in their adverse event spectra.

Per the ODYSSEY OUTCOMES investigators' own safety summary, discontinuation due to adverse events occurred in 12.1% of alirocumab patients versus 12.8% of placebo patients, a difference suggesting tolerability that is at minimum comparable to placebo-level background rates in a high-risk cardiac population.